Evidence map›Paper›PMID 33661356›Full record

ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2021

Long-term efficacy assessment of current treatment options for epistaxis in HHT.

Cilgia Dür, L Anschuetz, S Negoias, O C Bulut, A Angelillo-Scherrer, M Caversaccio

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Cilgia DürDepartment of Otorhinolaryngology, Head and Neck Surgery, Inselspital, University of Bern, Bern, Switzerland. cilgia.duer@insel.ch.ORCID http://orcid.org/0000-0002-9754-7269
L AnschuetzDepartment of Otorhinolaryngology, Head and Neck Surgery, Inselspital, University of Bern, Bern, Switzerland.
S NegoiasDepartment of ENT, Head and Neck Surgery, University of Basel, Basel, Switzerland.
O C BulutDepartment of ENT, University Heidelberg, 69120, Heidelberg, Germany.
A Angelillo-ScherrerDepartment of Hematology, Inselspital, University of Bern, Bern, Switzerland.
M CaversaccioDepartment of Otorhinolaryngology, Head and Neck Surgery, Inselspital, University of Bern, Bern, Switzerland.
University of Bern · CHHeidelberg University · DEUniversity of Basel · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeHereditary hemorrhagic telangiectasia (HHT) is a vascular disorder that presents with recurrent, intractable epistaxis. The aim of this study was to retrospectively analyze the efficacy of various treatment options for epistaxis in patients with HHT, over a period of 18 years, and to correlate these findings with available evidence in the literature.

methodsRecords of patients with HHT, treated for epistaxis between 2000 and 2018 were analyzed. Treatment procedures carried out and their efficacy were extracted and analyzed.

resultsForty-three records were evaluated. All patients were given nasal humidifying ointments, 93% required acute treatment with bipolar electrocautery, and 60% underwent atraumatic nasal packing. Recurrent cases were treated medically with tranexamic acid (26%), oestrogen (19%), and bevacizumab (2%). Laser photocoagulation was done in selected cases (40%) and if unsuccessful, septal dermoplasty was performed (2.3%). Endovascular embolization was reserved for life-threatening emergencies (7%).

conclusionEpistaxis in HHT is not curable, but can be managed by employing a comprehensive stepwise approach. An algorithm for effective and comprehensive management has been presented.

Indexed as

EpistaxisTelangiectasia, Hereditary HemorrhagicBevacizumabHumansLight CoagulationRetrospective StudiesBevacizumabBevacizumabEpistaxisHereditary hemorrhagic telangiectasiaLaser photocoagulationRendu-oslerRhinology

Identifiers

PMID33661356
PMCPMC8486717
OpenAlexW3135779239

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.